Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Soligenix Inc SNGX

Healthcare Biotechnology

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SNGX)

HyBryte(TM) Expanded Efficacy and Safety Data Presented at the American Academy of Dermatology Meeting

PR Newswire April 26, 2021

Soligenix Announces Presentations at Prominent Scientific Conferences

PR Newswire April 13, 2021

Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte(TM) for SGX301 in CTCL

PR Newswire April 7, 2021

Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results

PR Newswire March 30, 2021

Soligenix Anticipated to Achieve Multiple Milestones in 2021

Newsfile March 16, 2021

Soligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

PR Newswire March 9, 2021

Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine

PR Newswire March 4, 2021

Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter

PR Newswire February 24, 2021

Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track

Newsfile February 23, 2021

Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference

PR Newswire February 11, 2021

Soligenix's Upcoming Catalysts Highlight Growth Potential as it Sheds Light on its Commercialization of SGX301

Newsfile February 9, 2021

Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma

PR Newswire February 1, 2021

Soligenix Poised to Announce US Commercialization Plans of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma

Newsfile January 25, 2021

Soligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma

PR Newswire January 19, 2021

Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma

PR Newswire January 7, 2021

Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development

PR Newswire December 28, 2020

Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

PR Newswire December 22, 2020

Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing

PR Newswire December 16, 2020

Soligenix Demonstrates Extended Protection with its RiVax® Ricin Toxin Vaccine

PR Newswire December 8, 2020

Pfizer and Moderna COVID-19 Vaccine Candidates Are Promising, but Soligenix's Civax (TM) May Be a Better Alternative

Newsfile November 17, 2020